Share chart Krystal Biotech, Inc.
Extended chart
Simple chart
About Krystal Biotech, Inc.
Krystal Biotech, Inc., биотехнологическая компания клинической стадии, занимается генной терапией повторного применения для лечения серьезных редких заболеваний в Соединенных Штатах. Его ведущим продуктом-кандидатом является беремаген геперпавек (B-VEC), который находится в фазе III клинических исследований по лечению дистрофического буллезного эпидермолиза. more details| IPO date | 2017-09-20 |
|---|---|
| ISIN | US5011471027 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.krystalbio.com |
| Цена ао | 187.1 |
| Change price per week: | -0.6084% (166.01) |
|---|---|
| Change price per month: | -6.97% (177.37) |
| Change price per 3 month: | +9.77% (150.31) |
| Change price per half year: | -7.54% (178.46) |
| Change price per year: | -2.8% (169.75) |
| Change price per 3 year: | +140.91% (68.49) |
| Change price per 5 year: | +320.38% (39.25) |
| Change price per year to date: | +0.1031% (164.83) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Transaction date | Date of disclosure | Insider | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
|---|---|---|---|---|---|---|---|---|---|
| 28.02.2025 | 28.02.2025 | Krishnan Krish S President and CEO |
Purchase | 178.55 | 5 356 500 | 30000 | 0 | 0.12 | link |
| 28.02.2025 | 28.02.2025 | Krishnan Krish S President and CEO |
Purchase | 178.55 | 8 481 120 | 47500 | 0 | 0.19 | link |
| 28.02.2025 | 28.02.2025 | Krishnan Suma President, R&D |
Purchase | 178.55 | 8 481 120 | 47500 | 0 | 0.19 | link |
| 11.06.2024 | 11.06.2024 | Krishnan Krish S President and CEO |
Sale | 175.76 | 4 394 000 | 25000 | 0 | -0.1 | link |
| 11.06.2024 | 11.06.2024 | Krishnan Suma President, R&D |
Sale | 175.77 | 4 394 250 | 25000 | 0 | -0.1 | link |
| 28.02.2024 | 01.03.2024 | Krishnan Krish S President and CEO |
Purchase | 168.66 | 1 264 950 | 7500 | 0 | 0.03 | link |
| 28.02.2024 | 01.03.2024 | Krishnan Krish S President and CEO |
Purchase | 168.66 | 2 108 250 | 12500 | 0 | 0.05 | link |
| 28.02.2024 | 01.03.2024 | Krishnan Suma President, R&D |
Purchase | 168.66 | 2 108 250 | 12500 | 0 | 0.05 | link |
| 28.02.2024 | 01.03.2024 | Krishnan Suma President, R&D |
Purchase | 168.66 | 1 264 950 | 7500 | 0 | 0.03 | link |
| 28.02.2024 | 01.03.2024 | Romano Kathryn Chief Accounting Officer |
Sale | 166.05 | 1 245 380 | 7500 | 0 | -0.03 | link |
| 28.02.2024 | 01.03.2024 | Romano Kathryn Chief Accounting Officer |
Purchase | 63.55 | 476 625 | 7500 | 0 | 0.03 | link |
| 28.02.2024 | 01.03.2024 | Romano Kathryn Chief Accounting Officer |
Sale | 165.88 | 829 400 | 5000 | 0 | -0.02 | link |
| 28.02.2024 | 01.03.2024 | Romano Kathryn Chief Accounting Officer |
Purchase | 31.77 | 317 700 | 10000 | 0 | 0.04 | link |
| 09.06.2023 | 09.06.2023 | ORTH ANDREW C. Chief Commercial Officer |
Sale | 128.61 | 1 607 620 | 12500 | 0 | -0.05 | link |
| 09.06.2023 | 09.06.2023 | ORTH ANDREW C. Chief Commercial Officer |
Purchase | 63.55 | 794 375 | 12500 | 0 | 0.05 | link |
| 09.06.2023 | 09.06.2023 | JANNEY DANIEL Director |
Sale | 128.77 | 2 438 260 | 18935 | 0 | -0.08 | link |
| 08.06.2023 | 09.06.2023 | JANNEY DANIEL Director |
Sale | 128.11 | 3 979 740 | 31065 | 0 | -0.12 | link |
| Institutions | Volume | Share, % |
|---|---|---|
| Avoro Capital Advisors LLC | 2565555 | 9 |
| Vanguard Group Inc | 2435774 | 8.54 |
| FMR, LLC | 2385898 | 8.37 |
| Blackrock Inc. | 1809547 | 6.35 |
| Redmile Group, LLC | 1733189 | 6.08 |
| State Street Corporation | 1237497 | 4.34 |
| Frazier Life Sciences Management, L.P. | 988460 | 3.47 |
| Jennison Associates LLC | 724344 | 2.54 |
| Lord, Abbett & Co. LLC | 618458 | 2.17 |
| Dimensional Fund Advisors LP | 550806 | 1.93 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Jacob Forward ETF | 2.70262 | 43.03 | 0.15284 |
| AlphaMark Actively Managed Small Cap ETF | 0.92564 | 41.15 | 1.74611 |
| Future Tech ETF | 0.51487 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.51487 | 618.5 | 0.8416 |
| iShares Morningstar Small-Cap Growth ETF | 0.19941 | 596.94 | 0.72598 |
| Syntax Stratified SmallCap ETF | 0.15893 | 13.51 | 1.639 |
| iShares Morningstar Small-Cap ETF | 0.10009 | 391.25 | 1.60498 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Krish S. Krishnan M.B.A., M.S. | Founder, Chairman, President & CEO | 1.07M | 1965 (60 years) |
| Ms. Suma M. Krishnan | Founder, President of R&D and Director | 789.92k | 1965 (60 years) |
| Ms. Kathryn A. Romano | Executive VP & Chief Accounting Officer | 528.87k | 1982 (43 years) |
| Mr. John Karakkal | Vice President of North American Sales & Marketing | N/A | |
| Mr. Josh Suskin | Director of Human Resources & Operations | N/A | |
| Mr. Laurent Goux | Senior VP & GM of Europe | N/A | |
| Mr. John Thomas | General Counsel & Corporate Secretary | N/A | |
| Ms. Christine Wilson | Head of U.S. Sales & Marketing | N/A | |
| Dr. Stephane Paquette Ph.D. | Vice President of Corporate Development | ||
| Mr. David Chien | Senior Vice President of Clinical Development |
Address: United States, Pittsburgh. PA, 2100 Wharton Street - open in Google maps, open in Yandex maps
Website: https://www.krystalbio.com
Website: https://www.krystalbio.com
